JP2008534627A5 - - Google Patents

Download PDF

Info

Publication number
JP2008534627A5
JP2008534627A5 JP2008504532A JP2008504532A JP2008534627A5 JP 2008534627 A5 JP2008534627 A5 JP 2008534627A5 JP 2008504532 A JP2008504532 A JP 2008504532A JP 2008504532 A JP2008504532 A JP 2008504532A JP 2008534627 A5 JP2008534627 A5 JP 2008534627A5
Authority
JP
Japan
Prior art keywords
amylin
seq
disorder
disease
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008504532A
Other languages
English (en)
Japanese (ja)
Other versions
JP5114381B2 (ja
JP2008534627A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/012601 external-priority patent/WO2006105527A2/en
Publication of JP2008534627A publication Critical patent/JP2008534627A/ja
Publication of JP2008534627A5 publication Critical patent/JP2008534627A5/ja
Application granted granted Critical
Publication of JP5114381B2 publication Critical patent/JP5114381B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008504532A 2005-03-31 2006-03-31 精神疾患および障害治療用アミリンおよびアミリンアゴニスト Expired - Fee Related JP5114381B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US66668105P 2005-03-31 2005-03-31
US66733505P 2005-03-31 2005-03-31
US60/666,681 2005-03-31
US60/667,335 2005-03-31
US67544105P 2005-04-28 2005-04-28
US60/675,441 2005-04-28
US76058306P 2006-01-20 2006-01-20
US60/760,583 2006-01-20
PCT/US2006/012601 WO2006105527A2 (en) 2005-03-31 2006-03-31 Amylin and amylin agonists for treating psychiatric diseases and disorders

Publications (3)

Publication Number Publication Date
JP2008534627A JP2008534627A (ja) 2008-08-28
JP2008534627A5 true JP2008534627A5 (enExample) 2009-05-21
JP5114381B2 JP5114381B2 (ja) 2013-01-09

Family

ID=37054153

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008504396A Expired - Fee Related JP5415067B2 (ja) 2005-03-31 2006-03-31 肥満および摂食障害の制御、防止および治療のための組成物および方法
JP2008504532A Expired - Fee Related JP5114381B2 (ja) 2005-03-31 2006-03-31 精神疾患および障害治療用アミリンおよびアミリンアゴニスト

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008504396A Expired - Fee Related JP5415067B2 (ja) 2005-03-31 2006-03-31 肥満および摂食障害の制御、防止および治療のための組成物および方法

Country Status (17)

Country Link
US (7) US7671023B2 (enExample)
EP (5) EP2258382A3 (enExample)
JP (2) JP5415067B2 (enExample)
KR (3) KR101383493B1 (enExample)
CN (3) CN102343084A (enExample)
AT (2) ATE480255T1 (enExample)
AU (2) AU2006230420B2 (enExample)
BR (2) BRPI0609595A8 (enExample)
CA (2) CA2602261A1 (enExample)
DE (2) DE602006016760D1 (enExample)
DK (1) DK1888094T3 (enExample)
EA (1) EA013121B1 (enExample)
ES (1) ES2330671T3 (enExample)
IL (1) IL186200A (enExample)
MX (2) MX2007012237A (enExample)
NZ (3) NZ578299A (enExample)
WO (2) WO2006105527A2 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2008500281A (ja) * 2004-02-11 2008-01-10 アミリン・ファーマシューティカルズ,インコーポレイテッド アミリンファミリーペプチドおよびそれらを作成し使用するための方法
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
NZ578299A (en) 2005-03-31 2010-03-26 Amylin Pharmaceuticals Inc Amylin and amylin agonists for treating schizophrenia
WO2007014051A2 (en) * 2005-07-22 2007-02-01 Amylin Pharmaceuticals, Inc. Use of amylin and amylin agonists as cardioprotective or myoprotective agents
CN101400698A (zh) 2006-03-15 2009-04-01 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
US20090181890A1 (en) * 2006-03-31 2009-07-16 Amylin Pharmaceuticals , Inc. Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
MX2008012666A (es) * 2006-03-31 2008-10-13 Amylin Pharmaceuticals Inc Amilina y agonistas de amilina para tratar enfermedades y trastornos psiquiatricos.
ATE481963T1 (de) 2006-05-30 2010-10-15 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US8309522B2 (en) 2007-02-05 2012-11-13 Amylin Pharmaceuticals, Llc Neuromedin and FN-38 peptides for treating psychiatric diseases
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
EP2293811A1 (en) * 2008-06-25 2011-03-16 Novo Nordisk A/S Derivatised hybrid peptides of amylin and salmon calcitonin
JP5703226B2 (ja) * 2008-10-21 2015-04-15 ノヴォ ノルディスク アー/エス アミリン誘導体
LT2373681T (lt) 2008-12-10 2017-04-10 Glaxosmithkline Llc Albiglutido farmacinės kompozicijos
CA2750035C (en) * 2009-01-22 2018-02-27 Unigene Laboratories Inc. Treatment for obesity
EP2416797A4 (en) * 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
WO2010123930A2 (en) 2009-04-20 2010-10-28 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
KR102093612B1 (ko) 2009-09-28 2020-03-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
EP2566502A4 (en) 2010-05-04 2013-10-09 Glaxosmithkline Llc METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
WO2012000166A1 (zh) 2010-06-28 2012-01-05 中兴通讯股份有限公司 一种全封闭式综合接入系统及其降功耗的方法
WO2012054523A2 (en) 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
PT2661266T (pt) 2011-01-07 2020-11-30 Anji Pharma Us Llc Terapias com base em ligandos do recetor quimiossensorial
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
PH12013502517A1 (en) * 2011-06-17 2014-01-20 Hanmi Science Co Ltd A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
CN110693868A (zh) 2012-01-06 2020-01-17 埃尔舍利克斯治疗公司 双胍组合物和治疗代谢性病症的方法
CA2861392C (en) * 2012-01-26 2021-08-17 Christopher J. Soares Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
EP3027644B1 (en) * 2013-07-30 2019-08-21 Christopher J. Soares Cgrp agonist peptides
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3506925B1 (en) 2016-09-02 2023-09-06 Christopher J. Soares Use of cgrp receptor antagonists in treating glaucoma
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
WO2018132768A1 (en) * 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
EP3628233B1 (en) * 2018-09-28 2021-06-02 Siemens Healthcare GmbH Method and system for providing a dose reference value for a patient
US11443843B2 (en) 2019-01-04 2022-09-13 International Business Machines Corporation Personal customized guidance for treating patients
AU2020223284A1 (en) 2019-02-17 2021-09-16 Neurawell Therapeutics Compositions and methods for treatment of depression and other disorders
CN111700904A (zh) * 2020-07-31 2020-09-25 江南大学 一种利用酰化淀粉定点释放短链脂肪酸的抗抑郁的方法
JP2024527578A (ja) * 2021-07-08 2024-07-25 ギラ セラピューティクス インコーポレイテッド 神経受容体を活性化するための組成物及び方法
TW202530247A (zh) * 2023-12-04 2025-08-01 丹麥商西蘭製藥公司 方法
WO2025120002A1 (en) * 2023-12-04 2025-06-12 Zealand Pharma A/S Petrelintide for reducing weight whilst preserving lean mass

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3065460D1 (en) 1979-07-28 1983-12-08 Beecham Group Plc Benzocycloheptapyrrolealkanoic acids and their derivatives, processes for their preparation and pharmaceutical compositions containing them
US4397780A (en) 1982-02-12 1983-08-09 Armour Pharmaceutical Company Leucine22 -calcitonin
US4401593A (en) 1982-02-12 1983-08-30 Armour Pharmaceutical Company Glycine - 8 calcitonin
US4414149A (en) 1983-03-04 1983-11-08 Armour Pharmaceutical Company Glycine8 -D-arginine24 calcitonin
US4495097A (en) 1983-04-04 1985-01-22 Armour Pharmaceutical Company Des-serine2 -glycine8 calcitonin
US4497731A (en) 1983-04-04 1985-02-05 Armour Pharmaceutical Company Glycine 8-des-tyrosine 22 calcitonin
US4572208A (en) 1983-06-29 1986-02-25 Utah Medical Products, Inc. Metabolic gas monitoring apparatus and method
US4597900A (en) 1983-08-22 1986-07-01 Armour Pharmaceutical Co. Des2 -glycine8 -des22 -calcitonin
US4537716A (en) 1983-12-05 1985-08-27 Armour Pharmaceutical Co. Des-serine2 or des-glycine2 -leucine22 calcitonin
FI78231C (fi) 1984-11-21 1989-07-10 Instrumentarium Oy Maetanordning foer metaboliska storheter anslutbar till en respirator.
US4604238A (en) 1984-12-10 1986-08-05 Armour Pharmaceutical Company Analogs of calcitonin
US4606856A (en) 1985-03-18 1986-08-19 Seyler Jay K [Des-1-amino, 8-glycine]calcitonin
US4652627A (en) 1985-08-16 1987-03-24 Kempe Tomas G Calcitonin analogs with C-terminal D-amino acid substituents
US4687839A (en) 1985-12-23 1987-08-18 Kempe Tomas G Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents
US4697002A (en) 1985-12-23 1987-09-29 Kempe Tomas G Calcitonin gene related peptide analogs with amino acid subdstituents at the penultimate position 36
GB8709871D0 (en) 1987-04-27 1987-06-03 Turner R C Peptides
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5405831A (en) 1989-07-08 1995-04-11 Amylin Pharmaceuticals, Inc. Treatment of bone disorders
US5264372A (en) 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
WO1993010146A1 (en) * 1991-11-19 1993-05-27 Amylin Pharmaceuticals, Inc. Amylin agonist peptides and uses therefor
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
US6001364A (en) 1993-05-05 1999-12-14 Gryphon Sciences Hetero-polyoxime compounds and their preparation by parallel assembly
US5589356A (en) 1993-06-21 1996-12-31 Vanderbilt University Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement
CN1134110A (zh) 1993-09-07 1996-10-23 安米林药品公司 调节胃肠动力的方法
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6013009A (en) 1996-03-12 2000-01-11 Karkanen; Kip Michael Walking/running heart rate monitoring system
US5677279A (en) 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US6307018B1 (en) 1996-12-24 2001-10-23 The Scripps Research Institute General chemical ligation
WO1998030231A1 (en) 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6309360B1 (en) 1997-03-17 2001-10-30 James R. Mault Respiratory calorimeter
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US20040022807A1 (en) 1998-06-05 2004-02-05 Duft Bradford J Methods for treating obesity
CA2292724A1 (en) 1997-06-13 1998-12-17 Gryphon Sciences Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
EP1091440B1 (en) 1998-05-29 2010-06-02 JGC Catalysts and Chemicals Ltd. Method of manufacturing photoelectric cell
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
KR20010085743A (ko) 1998-08-31 2001-09-07 추후제출 지질 매트릭스 보조 화학결합 및 막 폴리펩티드의 합성
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
TW514510B (en) 1999-06-11 2002-12-21 Tanita Seisakusho Kk Method and apparatus for measuring distribution of body fat
US6468222B1 (en) 1999-08-02 2002-10-22 Healthetech, Inc. Metabolic calorimeter employing respiratory gas analysis
US6530886B1 (en) 1999-10-08 2003-03-11 Tanita Corporation Method and apparatus for measuring subcutaneous fat using ultrasonic wave
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
TW515705B (en) 2000-05-31 2003-01-01 Yamato Scale Co Ltd Visceral fat meter
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
JP2004518621A (ja) 2000-09-08 2004-06-24 グリフォン セラピューティクス,インコーポレーテッド 「擬似」天然型化学的ライゲーション
US6475158B1 (en) 2000-10-24 2002-11-05 Korr Medical Technologies, Inc. Calorimetry systems and methods
GB0113657D0 (en) 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
US20040138412A1 (en) 2001-09-07 2004-07-15 Paolo Botti Extended native chemical ligation
WO2003042235A2 (en) 2001-11-14 2003-05-22 Geneprot, Inc. Extended native chemical ligation of three or more peptide fragments
EP1474164B1 (en) 2002-01-08 2008-10-29 Amylin Pharmaceuticals, Inc. Use of amylin, amylin analogs and amylin derivatives to treat dyslipidemia and triglyceridemia
AR040126A1 (es) * 2002-05-29 2005-03-16 Glaxo Group Ltd Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
AU2003280206A1 (en) 2002-06-10 2004-02-02 Geneprot, Inc. Carboxy protection strategies for acidic c-terminal amino acids in chemical ligation of oligopeptides
WO2004048547A2 (en) 2002-11-26 2004-06-10 The Board Of Trustees Of The Leland Stanford Junior University Intermedin and its uses
US20060275768A1 (en) 2002-12-30 2006-12-07 Kochendoerfer Gerd G Multiplex polymer ligation
US20040197287A1 (en) * 2003-04-04 2004-10-07 The Procter & Gamble Company Personal care composition containing an antidandruff component and a nonionic surfactant
WO2004105685A2 (en) 2003-05-22 2004-12-09 Gryphon Therapeutics, Inc. Displaceable linker solid phase chemical ligation
JP2008500281A (ja) 2004-02-11 2008-01-10 アミリン・ファーマシューティカルズ,インコーポレイテッド アミリンファミリーペプチドおよびそれらを作成し使用するための方法
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
CA2580991A1 (en) 2004-10-08 2006-04-20 Amylin Pharmaceuticals, Inc. Amylin family polypeptide-6 (afp-6) analogs and methods of making and using them
NZ578299A (en) 2005-03-31 2010-03-26 Amylin Pharmaceuticals Inc Amylin and amylin agonists for treating schizophrenia

Similar Documents

Publication Publication Date Title
JP2008534627A5 (enExample)
JP2019031502A5 (enExample)
Bourne et al. Sleep disruption in critically ill patients–pharmacological considerations
Kruk-Slomka et al. Antidepressant-like effects of the cannabinoid receptor ligands in the forced swimming test in mice: mechanism of action and possible interactions with cholinergic system
JP2010535252A5 (enExample)
JP2014517050A5 (enExample)
JP2007523168A5 (enExample)
JP2005506370A5 (enExample)
JP2005500357A5 (enExample)
EP2283843A3 (en) Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
NO20092231L (no) Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav
HRP20120144T1 (en) Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
JP2008540356A (ja) 薬物乱用の治療方法
ATE451368T1 (de) Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems
JP2007516193A5 (enExample)
JP2014506933A5 (enExample)
JP2008535785A5 (enExample)
JP2022180531A5 (enExample)
MX2010009643A (es) Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a).
JP2008538582A (ja) 精神病性障害の治療または予防のための新規の治療的組み合わせ
JP2007509960A5 (enExample)
JP2011524898A5 (enExample)
JP2011500589A5 (enExample)
JP2010514682A5 (enExample)
JP2003511396A5 (enExample)